Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team. Kityo C, et al. Among authors: mambule i. PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014. PLoS One. 2014. PMID: 24625508 Free PMC article. Clinical Trial.
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P; DART Virology Group and Trial Team. Gilks CF, et al. Among authors: mambule i. Antivir Ther. 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19. Antivir Ther. 2012. PMID: 22814125 Clinical Trial.
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team. Paton NI, et al. Among authors: mambule i. N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274. N Engl J Med. 2014. PMID: 25014688 Free article. Clinical Trial.
The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe.
Chan AK, Ford D, Namata H, Muzambi M, Nkhata MJ, Abongomera G, Mambule I, South A, Revill P, Grundy C, Mabugu T, Chiwaula L, Cataldo F, Hakim J, Seeley J, Kityo C, Reid A, Katabira E, Sodhi S, Gilks CF, Gibb DM; Lablite Team. Chan AK, et al. Among authors: mambule i. BMC Health Serv Res. 2014 Aug 19;14:352. doi: 10.1186/1472-6963-14-352. BMC Health Serv Res. 2014. PMID: 25138583 Free PMC article.
Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study.
Nkhata MJ, Muzambi M, Ford D, Chan AK, Abongomera G, Namata H, Mambule I, South A, Revill P, Grundy C, Mabugu T, Chiwaula L, Hakim J, Kityo C, Reid A, Katabira E, Sodhi S, Gilks CF, Gibb DM, Seeley J, Cataldo F; Lablite team. Nkhata MJ, et al. Among authors: mambule i. BMC Health Serv Res. 2016 Nov 16;16(1):660. doi: 10.1186/s12913-016-1891-7. BMC Health Serv Res. 2016. PMID: 27852291 Free PMC article.
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Kityo C, et al. Among authors: mambule i. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285. J Acquir Immune Defic Syndr. 2017. PMID: 28129253 Free PMC article.
Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe-Africa Research Network for the Evaluation of Second-line Therapy trial.
Wanyama JN, Nabaggala MS, Wandera B, Kiragga AN, Castelnuovo B, Mambule IK, Nakajubi J, Kambugu AD, Paton NI, Wanyenze RK, Colebunders R, Easterbrook P. Wanyama JN, et al. Among authors: mambule ik. Int J STD AIDS. 2018 Mar;29(3):287-297. doi: 10.1177/0956462417724707. Epub 2017 Aug 17. Int J STD AIDS. 2018. PMID: 28814161
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Among authors: mambule ik. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
45 results